Generation of Tolerogenic Dendritic Cells for Lupus Treatment
Consorcio Tecnologico en Biomedicinaclinico-molecular S. A.
Mauricio Bulnes Bulnes Carrasco
MetadatosMostrar el registro completo del ítem
Generation of tolerogenic dendritic cells for lupus treatment. Systemic lupus erythematosus (SLE) is a chronic autoimmune disease of unknown etiology that preferentially targets women in childbearing age increasing the mortality rate as compared to the general population. Among the cellular components involved in the pathogenesis of lupus B cells and dendritic cells (DCs) has been reported as key players. DCs from SLE patients display an abnormally mature phenotype compared with DCs from healthy patients which contributes to the onset and maintainance of disease. In this context we propose to generate tolerogenic immature DC from peripheral blood of SLE patients render them resistant to maturation and use them as a therapy to recover immune tolerance. Immune modulation with tolerogenic DCs does not induce general immune supression because they will be loaded with specific SLE-antigens. Therefore it would not be associated with an increased susceptibility to pathogens and opportunistic infections which is one of most common complications of current available immunosuppressant therapies. Further this cell therapy application could also be implemented to treat other autoimmune diseases such as multiple sclerosis and rheumatoid arthritis. Previous data from our group suggest that tolerogenic DCs can be safe and eficient at reducing organ and systemic damage in experimental models for multiple sclerosis.